Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

124I-cG250 PET/CT in Early Detection of Response to Therapy in Patients with Advanced or Metastatic Kidney Cancer

Trial Status: closed to accrual

This pilot phase I/II trial studies how well iodine I-124 girentuximab (124I-cG250) positron emission tomography (PET)/computed tomography (CT) works in the early detection of response to therapy in patients with kidney cancer that has spread to other placed in the body. Diagnostic procedures, such as 124I-cG250 PET/CT, may detect the spread of tumor cells to other places in the body and help determine response to treatment.